SAN DIEGO--(BUSINESS WIRE)--Nutromics has presented world-first, real-time measurements of creatinine in humans using DNA-based sensors at American Society of Nephrology’s (ASN) Kidney Week 2026. The data comes from healthy participants wearing the company’s Lab-on-a-Patch™ and supports early detection and quantification of changing renal function. The company has also further deployed this wearable patch in the ICU in Australian hospital-based clinical studies.
DNA-based sensing is a platform technology with more than 24 targets demonstrated in animal models. Earlier this year, Nutromics demonstrated real-time drug monitoring in humans in its peer-reviewed Nature Biotechnology study. Creatinine is the first endogenous biomarker the company has monitored in real time in humans with additional studies on new biomarker sensors planned.
Creatinine is a biomarker hospitals routinely use to measure and track kidney function. Specifically, a trending rise in creatinine levels is associated with a decline in kidney function, which can happen during severe infections like sepsis, conditions like diabetes, or when dosing toxic medications, such as the antibiotic vancomycin. More generally, acute kidney injury (AKI) occurs in 10% - 20% of hospitalized patients in the United States and has been associated with up to US$24 billion in added hospitalization costs each year. Currently, detecting such a trend requires blood draws and laboratory testing. Such a paradigm fails to capture real-time changes in creatinine, leading to the delayed detection of kidney injury.